CytomX Therapeutics (CTMX) News
NASDAQ: CTMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.03-0.02 (-0.98%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CTMX news summary
We found 8 recent headlines mentioning CytomX Therapeutics (CTMX): 3 in the past week and 8 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, CTMX is down 0.98% at $2.03. The most recent story, "Regeneron Wins EC Clearance for Libtayo Dosing Flexibility", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest CytomX Therapeutics headlines
- Regeneron Wins EC Clearance for Libtayo Dosing FlexibilityREGN gains EC approval for flexible Libtayo dosing across six cancer indications, potentially improving patient convenience and strengthening its oncology business.NasdaqREGN, SNY, CTMX
- CytomX Earns $5 Million Milestone Payment As Regeneron Cancer Drug Collaboration Advances; Stock Up(RTTNews) - CytomX Therapeutics, Inc. (CTMX) announced the achievement of a preclinical milestone in its cancer research collaboration with Regeneron Pharmaceuticals, triggering a $5 million…NasdaqCTMX, HEI.A
- CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics- CytomX to receive $5 million preclinical milestone payment -GlobeNewswire
- CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business UpdateCytomX Therapeutics, Inc. reported its financial results for the quarter ended September 30, 2026. The company ended the quarter with $348.0 million of cash, cash equivalents and investments,…Nasdaq
- CytomX (CTMX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer -GlobeNewswire
- Qiagen (QGEN) Surpasses Q3 Earnings and Revenue EstimatesQiagen (QGEN) delivered earnings and revenue surprises of +3.18% and +1.56%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqQGEN, CTMX
- CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it…GlobeNewswire